Benzodiazepine Drugs Market to Reach US$ 3.2 Billion by 2034, Growing at 3.5% CAGR | Impact of Psychological Conditions and Aging Population - Reports TMR
07.08.2025 - 18:06:39 | prnewswire.co.ukCompetitive Landscape
Among different firms expanding in the industry, Pfizer Inc. is a key player that produces different products to expand. Such products include aminophylline, etomidate, argatroban injection, and many more.UCB S.A. is another important player producing solutions for Briviact (brivaracetam) Epilepsy, Ankylosing spondylitis, and Myasthenia Gravis.Hikma Pharmaceuticals PLC operates in different verticals, including injectables, oral drugs, and other segments.Key Developments in the Benzodiazepine Drug Market
In December 2023, Pfizer Inc. acquired Seagen. This move bolstered the position of the organization in the industry.In March 2024, UCB S.A. invested in IMIDomics, Inc. to innovate solutions for immune-mediated inflammatory diseases. This product launch helped the business augment products, bolstering the position in the market.Key Players
Pfizer Inc.UCB S.A.Hikma Pharmaceuticals PLCTeva Pharmaceutical Industries Ltd.H.Lundbeck A/SApotex Inc.Aurobindo PharmaPurdue PharmaOther Prominent PlayersMarket Segmentation
Drug Type
AlprazolamClonazepamDiazepamLorazepamOthers (Midazolam, etc.)Application
AnxietyInsomniaAlcohol WithdrawalSeizuresOthers (Bipolar Disorder, etc.)Time of Action
Ultra-short ActingShort ActingLong ActingEnd User
Hospital PharmaciesRetail PharmaciesOnline PharmaciesRegion
North AmericaEuropeAsia PacificLatin AmericaMiddle East & AfricaDrive Your Business Growth Strategy: Purchase the Report for Key Insights! https://www.transparencymarketresearch.com/checkout.php?rep_id=28424<ype=S
Have a Look at Related Research Reports of Pharmaceutical
Cardiovascular Drugs Market - The global cardiovascular drugs market, valued at USD 142.8 billion in 2022, is projected to grow at a compound annual growth rate (CAGR) of 3.8% from 2023 to 2031. This growth trajectory is expected to elevate the market size to USD 195.6 billion by the end of 2031, driven by increasing prevalence of cardiovascular diseases, advancements in drug development, and rising healthcare expenditures globally.Insomnia Market - The global insomnia industry was worth US$ 3.8 billion in 2022. From 2023 to 2031, it is expected to increase at a CAGR of 6.0%, reaching US$ 6.4 billion. Various therapies have been explored for managing insomnia, offering non-pharmacological alternatives for those seeking sleep improvement.Bioengineered Protein Drugs Market - Rise in incidence of chronic diseases such as infectious diseases, autoimmune disorders, and cancer is a dominating factor contributing to the bioengineered protein drugs market growth.About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn | Twitter | Blog | YouTube
Logo: https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg
View original content:
